Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNG | P07510 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRND | Q07001 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22923670 | 0.89 | GLP1R (0.73) | GLP1RLPAR3TLR2LPAR1NOD1 | |
| SCHEMBL27109909 | 0.88 | GLP1R (0.69) | GLP1RLPAR3TLR2CNR1LPAR1 | |
| SCHEMBL27117453 | 0.87 | GLP1R (0.68) | GLP1RLPAR3TLR2CNR1LPAR1 | |
| SCHEMBL15503597 | 0.85 | GLP1R (0.47) | GLP1RLPAR3TLR2CHRNA1CHRNG | |
| SCHEMBL27109668 | 0.85 | GLP1R (0.68) | GLP1RLPAR3TLR2LPAR1NOD1 | |
| SCHEMBL22055445 | 0.84 | GLP1R (0.65) | GLP1RLPAR3TLR2LPAR1NOD1 | |
| SCHEMBL18715474 | 0.84 | GLP1R (0.47) | GLP1RLPAR3TLR2LPAR1 | |
| SCHEMBL18715477 | 0.84 | GLP1R (0.47) | GLP1RLPAR3TLR2LPAR1 | |
| SCHEMBL26524137 | 0.83 | GLP1R (0.45) | GLP1RLPAR3TLR2CHRNA1CHRNG | |
| SCHEMBL18715473 | 0.83 | GLP1R (0.46) | GLP1RLPAR3TLR2CHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253875-A1 | Targeting Ligands For Therapeutic Compounds | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253875-A1 | Targeting Ligands For Therapeutic Compounds | FABP1, SNRPE, HAVCR2 | GLP1R 4316/4885LPAR3 512/4885TLR2 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.